This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Subscribe To Our Newsletter & Stay Updated
